Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ACCELERATE DIAGNOSTICS, INC.

(AXDX)
  Report
Delayed Nasdaq  -  04:00:00 2023-02-03 pm EST
0.6891 USD   -4.36%
01/13Accelerate Diagnostics, Inc : Other Events (form 8-K)
AQ
01/11Accelerate Diagnostics, Inc : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
2022Accelerate Diagnostics Files Application With US FDA to Update PhenoTest BC Kit
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Certain Stock Options of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 17-NOV-2022.

11/17/2022 EST

Certain Stock Options of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement Ending on 17-NOV-2022. These Stock Options will be under lockup for 91 days starting from 18-AUG-2022 to 17-NOV-2022.

Details:
The directors, executive officers, and certain of significant shareholders have agreed that they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, any shares of common stock or any securities convertible into or exercisable or exchangeable for common stock, for a period of 90 days after the date of the final prospectus without the prior written consent of J.P. Morgan Securities LLC.


ę S&P Capital IQ 2022
All news about ACCELERATE DIAGNOSTICS, INC.
01/13Accelerate Diagnostics, Inc : Other Events (form 8-K)
AQ
01/11Accelerate Diagnostics, Inc : Notice of Delisting or Failure to Satisfy a Continued Listin..
AQ
2022Accelerate Diagnostics Files Application With US FDA to Update PhenoTest BC Kit
MT
2022Accelerate Diagnostics submits 510(K) application to FDA for Gram-negative menu expansi..
PR
2022Accelerate Diagnostics Submits 510(K) Application to FDA for Gram-Negative Menu Expansi..
CI
2022Accelerate Diagnostics, Inc : Change in Directors or Principal Officers, Financial Stateme..
AQ
2022Accelerate Diagnostics, Inc. Announces Resignation of Ron Price as Chief Commercial Off..
CI
2022Certain Warrants of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement End..
CI
2022Certain Stock Options of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreemen..
CI
2022Certain Common Stock of Accelerate Diagnostics, Inc. are subject to a Lock-Up Agreement..
CI
More news
Analyst Recommendations on ACCELERATE DIAGNOSTICS, INC.
More recommendations
Financials (USD)
Sales 2022 12,7 M - -
Net income 2022 -60,3 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,91x
Yield 2022 -
Capitalization 68,3 M 68,3 M -
Capi. / Sales 2022 5,40x
Capi. / Sales 2023 3,99x
Nbr of Employees 220
Free-Float 73,2%
Chart ACCELERATE DIAGNOSTICS, INC.
Duration : Period :
Accelerate Diagnostics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACCELERATE DIAGNOSTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Last Close Price 0,69 $
Average target price 2,00 $
Spread / Average Target 190%
EPS Revisions
Managers and Directors
Jack Phillips President, Chief Executive Officer & Director
Steven Reichling Chief Financial & Accounting Officer
John Patience Chairman
Lawrence Mertz Chief Technology Officer
Jack W. Schuler Independent Director
Sector and Competitors